GTBP Current Deferred Revenue vs Short Term Debt Analysis
GTBP Stock | USD 3.52 0.05 1.40% |
GT Biopharma financial indicator trend analysis is much more than just examining GT Biopharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GT Biopharma is a good investment. Please check the relationship between GT Biopharma Current Deferred Revenue and its Short Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Current Deferred Revenue vs Short Term Debt
Current Deferred Revenue vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GT Biopharma Current Deferred Revenue account and Short Term Debt. At this time, the significance of the direction appears to have strong relationship.
The correlation between GT Biopharma's Current Deferred Revenue and Short Term Debt is 0.67. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of GT Biopharma, assuming nothing else is changed. The correlation between historical values of GT Biopharma's Current Deferred Revenue and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of GT Biopharma are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Current Deferred Revenue i.e., GT Biopharma's Current Deferred Revenue and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.67 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Short Term Debt
Most indicators from GT Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Selling General Administrative is relatively stable compared to the past year. As of 06/05/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Sales General And Administrative To Revenue is likely to drop 2.17.
2023 | 2024 (projected) | Total Operating Expenses | 13.6M | 10.7M | Cost Of Revenue | 3.6K | 3.4K |
GT Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Liab | 4.4M | 383K | 138K | 1.7M | 2.2M | 2.3M | |
Total Current Liabilities | 19.7M | 35.1M | 10.3M | 4.9M | 6.6M | 6.9M | |
Total Stockholder Equity | (19.1M) | (29.3M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Net Debt | 13.3M | 21.0M | (8.9M) | (5.5M) | (1.0M) | (970.0K) | |
Retained Earnings | (567.3M) | (595.6M) | (653.6M) | (674.5M) | (682.1M) | (648.0M) | |
Accounts Payable | 1.9M | 2.2M | 8.2M | 3.1M | 4.3M | 4.5M | |
Cash | 28K | 5.3M | 9.0M | 5.7M | 1.1M | 1.2M | |
Non Current Assets Total | 25.3M | 122K | 0.0 | 174K | 53K | 50.4K | |
Cash And Short Term Investments | 28K | 5.3M | 32.0M | 16.5M | 14.0M | 14.7M | |
Common Stock Total Equity | 50K | 51K | 70K | 52K | 46.8K | 44.5K | |
Common Stock Shares Outstanding | 112.8K | 146.2K | 938.5K | 1.1M | 1.3M | 1.3M | |
Liabilities And Stockholders Equity | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Assets | 246K | 364K | 190K | 54K | 84K | 79.8K | |
Other Stockholder Equity | 548.1M | 566.3M | 673.2M | 686.2M | 689.5M | 724.0M | |
Total Liab | 19.7M | 35.1M | 10.3M | 5.0M | 6.6M | 7.1M | |
Property Plant And Equipment Gross | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Total Current Assets | 274K | 5.7M | 32.2M | 16.6M | 14.1M | 14.8M | |
Common Stock | 70K | 52K | 1.1M | 33K | 1K | 950.0 | |
Short Long Term Debt Total | 10.8M | 13.4M | 26.3M | 174K | 58K | 55.1K | |
Short Term Debt | 10.8M | 13.4M | 26.3M | 110K | 58K | 55.1K | |
Net Tangible Assets | (13.7M) | (19.1M) | (29.3M) | 21.9M | 25.2M | 26.5M | |
Short Long Term Debt | 31K | 10.8M | 13.2M | 26.3M | 35.7K | 33.9K | |
Net Invested Capital | (5.9M) | (2.9M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Net Working Capital | (19.4M) | (29.4M) | 21.9M | 11.6M | 7.4M | 7.8M | |
Capital Stock | 73K | 55K | 1.1M | 34K | 2K | 1.9K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.